Literature DB >> 17673478

Biochemical analysis of TEM-134, a new TEM-type extended-spectrum beta-lactamase variant produced in a Citrobacter koseri clinical isolate from an Italian hospital.

Mariagrazia Perilli1, Giuseppe Celenza, Marianna Fiore, Bernardetta Segatore, Cristina Pellegrini, Francesco Luzzaro, Gian Maria Rossolini, Gianfranco Amicosante.   

Abstract

OBJECTIVES: Kinetic characterization of TEM-134, a new TEM-type extended-spectrum beta-lactamase variant isolated from Citrobacter koseri during an Italian nationwide survey. TEM-134 is a natural derivative of TEM-2 with the following substitutions: E104K, R164H and G238S.
METHODS: Recombinant TEM-134 was purified from Escherichia coli HB101 (pMGP-134) by three chromatographic steps (cation-exchange chromatography, gel permeation and fast chromatofocusing). Steady-state kinetic parameters (K(m) and k(cat)) were determined by measuring substrate hydrolysis under initial rate conditions using the Hanes linearization of the Michaelis-Menten equation. Modelling was carried out using the software Modeller (version 9.1).
RESULTS: TEM-134 hydrolysed with variable efficiency (k(cat)/K(m) ranging from 5 x 10(3) to 8.0 x 10(5) M(-1) . s(-1)) penicillins, narrow-spectrum cephalosporins, cefepime, cefotaxime, ceftazidime and aztreonam, which appeared to be the best substrate. Molecular modelling of the enzyme indicated that the R164H substitution may result in a compromised omega loop in TEM-134 and this may be responsible for its narrower spectrum of activity.
CONCLUSIONS: Kinetic data and molecular modelling suggested that R164H has a mild detrimental effect on the global activity of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673478     DOI: 10.1093/jac/dkm275

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.

Authors:  Mariagrazia Perilli; Giuseppe Celenza; Francesca De Santis; Cristina Pellegrini; Chiara Forcella; Gian Maria Rossolini; Stefania Stefani; Gianfranco Amicosante
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

2.  R164H and V240H replacements by site-directed mutagenesis of TEM-149 extended-spectrum β-lactamase: kinetic analysis of TEM-149H240 and TEM-149H164-H240 laboratory mutants.

Authors:  Mariagrazia Perilli; Giuseppe Celenza; Paola Sandra Mercuri; Moreno Galleni; Cristina Pellegrini; Bernardetta Segatore; Gianfranco Amicosante
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

3.  Kinetic study of the effect of histidines 240 and 164 on TEM-149 enzyme probed by β-lactam inhibitors.

Authors:  Mariagrazia Perilli; Alisia Mancini; Giuseppe Celenza; Carlo Bottoni; Pierangelo Bellio; Alessia Sabatini; Letizia Di Pietro; Fabrizia Brisdelli; Bernardetta Segatore; Gianfranco Amicosante
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

4.  Prevalence of the bla (SHV) gene in Klebsiella pneumoniae isolates obtained from hospital and community infections and from the microbiota of healthy individuals in Recife, Brazil.

Authors:  Dyana Leal Veras; Luiz Carlos Alves; Fábio André Brayner; Duschinka Ribeiro Duarte Guedes; Maria Amélia Vieira Maciel; Cíntia Renata Costa Rocha; Ana Catarina de Souza Lopes
Journal:  Curr Microbiol       Date:  2011-02-27       Impact factor: 2.188

5.  Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155.

Authors:  C Hal Jones; Alexey Ruzin; Margareta Tuckman; Melissa A Visalli; Peter J Petersen; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.